An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products

Since legalization, cannabis/marijuana has been gaining considerable attention as a functional ingredient in food. ∆-9 tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids are key bioactive compounds with health benefits. The oral consumption of cannabis transports much less hazardous chemicals than smoking. Nevertheless, the response to cannabis is biphasically dose-dependent (hormesis; a low-dose stimulation and a high-dose inhibition) with wide individuality in responses. Thus, the exact same dose and preparation of cannabis may be beneficial for some but toxic to others. The purpose of this review is to highlight the concept of individual variations in response to cannabinoids, which leads to the challenge of establishing standard safe doses of cannabis products for the general population. The mechanisms of actions, acute and chronic toxicities, and factors affecting responses to cannabis products are updated. Based on the literature review, we found that the response to cannabis products depends on exposure factors (delivery route, duration, frequency, and interactions with food and drugs), individual factors (age, sex), and susceptibility factors (genetic polymorphisms of cannabinoid receptor gene, N-acylethanolamine-hydrolyzing enzymes, THC-metabolizing enzymes, and epigenetic regulations). Owing to the individuality of responses, the safest way to use cannabis-containing food products is to start low, go slow, and stay low.

[1]  P. Lazarus,et al.  Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy , 2022, Expert review of clinical pharmacology.

[2]  Lillianne H Wright,et al.  Perspectives on Challenges in Cannabis Drug Delivery Systems: Where Are We? , 2022, Medical Cannabis and Cannabinoids.

[3]  D. Lachenmeier,et al.  The Challenge of Risk Assessment of Tetrahydrocannabinol (THC) in Cannabidiol (CBD) Oils and Food Supplements: An Approach for Deriving Maximum Limits , 2022, Challenges.

[4]  S. Procaccia,et al.  Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug , 2022, Frontiers in Pharmacology.

[5]  Di Wu,et al.  Cannabis sativa Bioactive Compounds and Their Extraction, Separation, Purification, and Identification Technologies: An Updated Review , 2022, TrAC Trends in Analytical Chemistry.

[6]  K. Vrana,et al.  Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals , 2022, Pharmacology.

[7]  A. Seyfoddin,et al.  Medicinal cannabis pharmacokinetics and potential methods of delivery , 2022, Pharmaceutical development and technology.

[8]  A. Ebadi,et al.  THC and CBD Fingerprinting of an Elite Cannabis Collection from Iran: Quantifying Diversity to Underpin Future Cannabis Breeding , 2022, Plants.

[9]  D. Pate,et al.  A broader view on deriving a reference dose for THC traces in foods , 2021, Critical reviews in toxicology.

[10]  K. Allegaert,et al.  Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis , 2021, Scientific Reports.

[11]  A. Dalai,et al.  Cannabis: Chemistry, extraction and therapeutic applications. , 2021, Chemosphere.

[12]  M. Bryła,et al.  Cannabinoids—Characteristics and Potential for Use in Food Production , 2021, Molecules.

[13]  M. Medina-Mora,et al.  Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. , 2021, The International journal on drug policy.

[14]  Kristine Rømer Thomsen,et al.  Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample , 2021, Harm Reduction Journal.

[15]  A. K. Mishra,et al.  Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview , 2021, Phytotherapy research : PTR.

[16]  D. Vergara,et al.  The phytochemical diversity of commercial Cannabis in the United States , 2021, bioRxiv.

[17]  Christine M. Wickens,et al.  Influence of Cannabinoid Receptor 1 Genetic Variants on the Subjective Effects of Smoked Cannabis , 2021, International journal of molecular sciences.

[18]  E. Morris,et al.  Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit , 2021, Medical Cannabis and Cannabinoids.

[19]  F. O. Holguin,et al.  The Effects of Food on Cannabidiol Bioaccessibility , 2021, Molecules.

[20]  K. Sharma,et al.  Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health , 2021 .

[21]  S. Bhattacharyya,et al.  Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis , 2021, PLoS medicine.

[22]  S. Bufo,et al.  Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses , 2021, Toxins.

[23]  H. Thorpe,et al.  High genes: Genetic underpinnings of cannabis use phenotypes , 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  S. Chayasirisobhon Mechanisms of Action and Pharmacokinetics of Cannabis. , 2020, The Permanente journal.

[25]  F. Thibaut,et al.  Cannabinoids: for better and for worse
 , 2020, Dialogues in clinical neuroscience.

[26]  V. Giampietro,et al.  Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence , 2020, Frontiers in Psychiatry.

[27]  H. Köhler,et al.  Toxicogenetic analysis of Δ9-THC-metabolizing enzymes , 2020, International Journal of Legal Medicine.

[28]  J. Tytgat,et al.  Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products , 2020, International journal of molecular sciences.

[29]  R. Or,et al.  Cannabis, the Endocannabinoid System and Immunity—the Journey from the Bedside to the Bench and Back , 2020, International journal of molecular sciences.

[30]  L. Parker,et al.  Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms. , 2020, Cannabis and cannabinoid research.

[31]  Somenath Ghosh Cannabis Effect on Female Reproductive Health , 2020, Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health.

[32]  R. Capasso,et al.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? , 2020, International journal of molecular sciences.

[33]  Joshua D. Brown Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions , 2020, Journal of clinical medicine.

[34]  R. Coppock,et al.  Safety Assessment of a Hemp Extract using Genotoxicity and Oral Repeat-Dose Toxicity Studies in Sprague-Dawley Rats , 2020, Toxicology Reports.

[35]  D. Critchley,et al.  A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects , 2020, Epilepsia.

[36]  Donatella Fiore,et al.  The Endocannabinoid System: A Target for Cancer Treatment , 2020, International journal of molecular sciences.

[37]  Natalie Hemsing,et al.  Sex and Gender Interactions on the Use and Impact of Recreational Cannabis , 2020, International journal of environmental research and public health.

[38]  D. Arcella,et al.  Acute human exposure assessment to tetrahydrocannabinol (Δ9‐THC) , 2020, EFSA journal. European Food Safety Authority.

[39]  J. Fischedick,et al.  Cannabinoids and Terpenes as Chemotaxonomic markers in Cannabis , 2015, Prime Archives in Chemistry.

[40]  Bryan W. Jenkins,et al.  Adolescent Neurodevelopment and Substance Use: Receptor Expression and Behavioral Consequences. , 2019, Pharmacology & therapeutics.

[41]  N. Gemmell,et al.  Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort , 2019, bioRxiv.

[42]  C. Baum,et al.  Acute Cannabis Toxicity. , 2019, Pediatric emergency care.

[43]  J. Caulkins,et al.  Public health implications of legalising the production and sale of cannabis for medicinal and recreational use , 2019, The Lancet.

[44]  M. Roth,et al.  Pulmonary effects of inhaled cannabis smoke , 2019, The American journal of drug and alcohol abuse.

[45]  L. C. Bidwell,et al.  CNR1 and FAAH variation and affective states induced by marijuana smoking , 2019, The American journal of drug and alcohol abuse.

[46]  Abraham Weizman,et al.  Positive and Negative Effects of Cannabis and Cannabinoids on Health , 2019, Clinical pharmacology and therapeutics.

[47]  E. Bramon,et al.  Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme , 2019, Addiction biology.

[48]  J. Hotaling,et al.  Cannabis and Male Fertility: A Systematic Review. , 2019, The Journal of urology.

[49]  Y. Sarne Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC , 2019, The American journal of drug and alcohol abuse.

[50]  A. Duarte,et al.  Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination , 2019, Medicines.

[51]  O. Viswanath,et al.  An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine , 2019, Pain and Therapy.

[52]  K. Hedberg,et al.  Acute cannabis toxicity , 2019, Clinical toxicology.

[53]  Ashley N. Linden-Carmichael,et al.  Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults , 2018, Addiction.

[54]  M. Daly,et al.  Genome-wide association study implicates CHRNA2 in cannabis use disorder , 2017, Nature Neuroscience.

[55]  E. Groce The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research , 2018, Journal of Medical Regulation.

[56]  M. Memo,et al.  Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. , 2018, Journal of ethnopharmacology.

[57]  C. Lucas,et al.  The pharmacokinetics and the pharmacodynamics of cannabinoids. , 2018, British journal of clinical pharmacology.

[58]  L. Thabane,et al.  The effect of cannabis exposure on pubertal outcomes: a systematic review , 2018, Adolescent health, medicine and therapeutics.

[59]  S. Myung,et al.  Cannabis Smoking and Risk of Cancer: A Meta-Analysis of Observational Studies , 2018, Journal of Global Oncology.

[60]  A. Csoka,et al.  Epigenetic Effects of Drugs of Abuse , 2018, International journal of environmental research and public health.

[61]  Zachary F. Gerring,et al.  GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability , 2018, Nature Neuroscience.

[62]  Hongyu Zhao,et al.  Genome‐wide association meta‐analysis of age at first cannabis use , 2018, Addiction.

[63]  V. Marzo New approaches and challenges to targeting the endocannabinoid system , 2018, Nature Reviews Drug Discovery.

[64]  S. Khalid,et al.  Risk Factors and Management of Takotsubo Cardiomyopathy , 2018, Cureus.

[65]  E. Calabrese,et al.  Biphasic effects of THC in memory and cognition , 2018, European journal of clinical investigation.

[66]  G. Murray,et al.  Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis , 2018, The British Journal of Psychiatry.

[67]  U. Kumar,et al.  Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System , 2018, International journal of molecular sciences.

[68]  Ethan B. Russo,et al.  Practical considerations in medical cannabis administration and dosing. , 2018, European journal of internal medicine.

[69]  Jennifer H. Martin,et al.  Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? , 2018, Clinical Pharmacokinetics.

[70]  J. Richards,et al.  Unintentional Cannabis Ingestion in Children: A Systematic Review , 2017, The Journal of pediatrics.

[71]  T. Wilens,et al.  Medical Cannabinoids in Children and Adolescents: A Systematic Review , 2017, Pediatrics.

[72]  R. Desai,et al.  Recreational Marijuana Use and Acute Myocardial Infarction: Insights from Nationwide Inpatient Sample in the United States , 2017, Cureus.

[73]  W. Corbin,et al.  Developmentally Specific Associations Between CNR1 Genotype and Cannabis Use Across Emerging Adulthood. , 2017, Journal of studies on alcohol and drugs.

[74]  A. Köfalvi,et al.  Cannabis: A Treasure Trove or Pandora's Box? , 2017, Mini reviews in medicinal chemistry.

[75]  Yong Zhao,et al.  Bioactive spirans and other constituents from the leaves of Cannabis sativa f. sativa , 2017, Journal of Asian natural products research.

[76]  R. Tandon,et al.  Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders , 2017, Current neuropharmacology.

[77]  A. Auton,et al.  Replication and characterization of CADM2 and MSRA genes on human behavior , 2017, bioRxiv.

[78]  M. Elsohly,et al.  Phytochemistry of Cannabis sativa L. , 2017, Progress in the chemistry of organic natural products.

[79]  Bharathi Avula,et al.  Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry , 2016, Cannabis and cannabinoid research.

[80]  Silas B. Tittes,et al.  Genetic and Genomic Tools for Cannabis sativa , 2016 .

[81]  B. Jones,et al.  Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate , 2016, Psychiatry Research: Neuroimaging.

[82]  Qing-Rong Liu,et al.  Human CB1 Receptor Isoforms, present in Hepatocytes and β-cells, are Involved in Regulating Metabolism , 2016, Scientific Reports.

[83]  C. Constantinescu,et al.  Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. , 2016, American journal of translational research.

[84]  C. Cuttler,et al.  Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users , 2016, Cannabis and cannabinoid research.

[85]  Y. Hurd,et al.  Epigenetic Effects of Cannabis Exposure , 2016, Biological Psychiatry.

[86]  T. Spector,et al.  Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium , 2016, Translational Psychiatry.

[87]  C. Andre,et al.  Cannabis sativa: The Plant of the Thousand and One Molecules , 2016, Front. Plant Sci..

[88]  J. Kahn,et al.  Myocarditis associated with cannabis use in a 15-year-old boy: A rare case report. , 2016, International journal of cardiology.

[89]  J. Collet,et al.  Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). , 2015, The journal of pain : official journal of the American Pain Society.

[90]  S. Mandal,et al.  Cannabis smoke can be a major risk factor for early-age laryngeal cancer—a molecular signaling-based approach , 2015, Tumor Biology.

[91]  F. Verhulst,et al.  Catechol‐O‐methyltransferase gene methylation and substance use in adolescents: the TRAILS study , 2014, Genes, brain, and behavior.

[92]  C. Lançon,et al.  Acute and long-term effects of cannabis use: a review. , 2014, Current pharmaceutical design.

[93]  V. Calhoun,et al.  Methylation patterns in whole blood correlate with symptoms in schizophrenia patients. , 2014, Schizophrenia bulletin.

[94]  M. Nagarkatti,et al.  Histone Modifications Are Associated with Δ9-Tetrahydrocannabinol-mediated Alterations in Antigen-specific T Cell Responses* , 2014, The Journal of Biological Chemistry.

[95]  D. Fergusson,et al.  Mid-ventricular variant takotsubo cardiomyopathy associated with Cannabinoid Hyperemesis Syndrome: a case report. , 2014, Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health.

[96]  S. Ritz‐Timme,et al.  Sudden unexpected death under acute influence of cannabis. , 2014, Forensic science international.

[97]  R. Verkes,et al.  Efficacy and safety of medical cannabinoids in older subjects: A systematic review , 2014, Ageing Research Reviews.

[98]  P. Molina,et al.  Chronic Administration of Δ9-Tetrahydrocannabinol Induces Intestinal Anti-Inflammatory MicroRNA Expression during Acute Simian Immunodeficiency Virus Infection of Rhesus Macaques , 2014, Journal of Virology.

[99]  H. Morgenstern,et al.  Association of Marijuana Smoking with Oropharyngeal and Oral Tongue Cancers: Pooled Analysis from the INHANCE Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[100]  M. Nagarkatti,et al.  Distinct MicroRNA Expression Profile and Targeted Biological Pathways in Functional Myeloid-derived Suppressor Cells Induced by Δ9-Tetrahydrocannabinol in Vivo , 2013, The Journal of Biological Chemistry.

[101]  G. Panagis,et al.  Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. , 2013, The international journal of neuropsychopharmacology.

[102]  E. Calabrese Hormetic mechanisms , 2013, Critical reviews in toxicology.

[103]  G. Guy,et al.  A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers , 2013, SpringerPlus.

[104]  S. Iliffe,et al.  Frailty in elderly people , 2013, The Lancet.

[105]  J. Martínez-Orgado,et al.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? , 2013, British journal of clinical pharmacology.

[106]  Ming D. Li,et al.  Significant associations of CHRNA2 and CHRNA6 with nicotine dependence in European American and African American populations , 2013, Human Genetics.

[107]  E. Nestler,et al.  Proenkephalin Mediates the Enduring Effects of Adolescent Cannabis Exposure Associated with Adult Opiate Vulnerability , 2012, Biological Psychiatry.

[108]  B. Lutz,et al.  Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission , 2012, Neuropsychopharmacology.

[109]  P. Castillo,et al.  Endocannabinoid Signaling and Synaptic Function , 2012, Neuron.

[110]  Florence T. Bourgeois,et al.  Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease Burden , 2012, Pediatrics.

[111]  Joseph P. Schacht,et al.  Associations between Cannabinoid Receptor-1 (CNR1) Variation and Hippocampus and Amygdala Volumes in Heavy Cannabis Users , 2012, Neuropsychopharmacology.

[112]  Lex Denysenko,et al.  Cannabinoid hyperemesis syndrome: a case series and review of previous reports. , 2012, Psychosomatics.

[113]  F. Friedenberg,et al.  Cannabinoid hyperemesis syndrome. , 2011, Current drug abuse reviews.

[114]  Y. Hurd,et al.  Maternal Cannabis Use Alters Ventral Striatal Dopamine D2 Gene Regulation in the Offspring , 2011, Biological Psychiatry.

[115]  Lawrence J. Marnett,et al.  Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways , 2011, Chemical reviews.

[116]  Bita Moghaddam,et al.  The neurobiology of adolescence: Changes in brain architecture, functional dynamics, and behavioral tendencies , 2011, Neuroscience & Biobehavioral Reviews.

[117]  R. Hancox,et al.  Effects of smoking cannabis on lung function , 2011, Expert review of respiratory medicine.

[118]  Ethan B. Russo Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects , 2011, British journal of pharmacology.

[119]  M. Bortolato,et al.  Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis , 2010, Pharmaceuticals.

[120]  R. Bevins,et al.  Cannabinoid conditioned reward and aversion: behavioral and neural processes. , 2010, ACS chemical neuroscience.

[121]  P. Piazza,et al.  Bimodal control of stimulated food intake by the endocannabinoid system , 2010, Nature Neuroscience.

[122]  Ursula S. Myers,et al.  Individual and Additive Effects of the CNR1 and FAAH Genes on Brain Response to Marijuana Cues , 2010, Neuropsychopharmacology.

[123]  R. Abdel-Hady,et al.  Subchronic toxicity of cannabis leaves on male albino rats , 2010, Human & experimental toxicology.

[124]  J. Hewitt,et al.  The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. , 2009, Drug and alcohol dependence.

[125]  Shufeng Zhou,et al.  Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. , 2009, Current drug metabolism.

[126]  G. Uhl,et al.  Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands , 2009, Genes, brain, and behavior.

[127]  A. Reece Chronic toxicology of cannabis , 2009, Clinical toxicology.

[128]  Chu Chen,et al.  Association of marijuana use and the incidence of testicular germ cell tumors , 2009, Cancer.

[129]  A. Heath,et al.  Examination of the nicotine dependence (NICSNP) consortium findings in the Iowa adoption studies population. , 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[130]  Masahiko Watanabe,et al.  Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.

[131]  Joseph P. Schacht,et al.  Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis , 2009, Psychopharmacology.

[132]  K. Straif,et al.  Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled Analysis of Three Studies in Maghreb , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[133]  Kent E Hutchison,et al.  Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. , 2008, Addiction.

[134]  A. Hansell,et al.  Cannabis use and risk of lung cancer: a case–control study , 2008, European Respiratory Journal.

[135]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[136]  C. Ledent,et al.  The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[137]  M. Elsohly Marijuana and the Cannabinoids , 2007 .

[138]  M. Huestis Human Cannabinoid Pharmacokinetics , 2007, Chemistry & biodiversity.

[139]  Peter B. Jones,et al.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.

[140]  R. Tyndale,et al.  The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[141]  R. Brenneisen Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents , 2007 .

[142]  K. Straif,et al.  Risk of Lung Cancer and Past Use of Cannabis in Tunisia , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  A. Olshan,et al.  Maternal Use of Recreational Drugs and Neuroblastoma in Offspring: A Report from the Children’s Oncology Group (United States) , 2006, Cancer Causes & Control.

[144]  Thomas A. Briellmann,et al.  Isolation of Δ9-THCA-A from hemp and analytical aspects concerning the determination of Δ9-THC in cannabis products , 2005 .

[145]  H. Morgenstern,et al.  Epidemiologic review of marijuana use and cancer risk. , 2005, Alcohol.

[146]  K. Mackie,et al.  Distribution of cannabinoid receptors in the central and peripheral nervous system. , 2005, Handbook of experimental pharmacology.

[147]  M. Luginbühl,et al.  Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. , 2005, Forensic science international.

[148]  M. Huestis Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. , 2005, Handbook of experimental pharmacology.

[149]  Robert I. Block,et al.  Effects of chronic marijuana use on human cognition , 2005, Psychopharmacology.

[150]  J. Os,et al.  Early adolescent cannabis exposure and positive and negative dimensions of psychosis. , 2004, Addiction.

[151]  S. Sidney,et al.  The Risk for Malignant Primary Adult-Onset Glioma in a Large, Multiethnic, Managed-Care Cohort: Cigarette Smoking and Other Lifestyle Behaviors , 2004, Journal of Neuro-Oncology.

[152]  A. Ullrich,et al.  Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor , 2004, Cancer Research.

[153]  P. Routledge,et al.  Adverse drug reactions in elderly patients. , 2003, British journal of clinical pharmacology.

[154]  G. Friedman,et al.  Marijuana use and cancer incidence (California, United States) , 1997, Cancer Causes & Control.

[155]  S. A. Turkanis,et al.  Excitatory and depressant effects of Δ9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat , 2004, Psychopharmacology.

[156]  E. Tzavara,et al.  Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action , 2003, The Journal of Neuroscience.

[157]  D. Fergusson,et al.  Cannabis dependence and psychotic symptoms in young people , 2003, Psychological Medicine.

[158]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.

[159]  D. Ford,et al.  Marijuana Smoking and Head and Neck Cancer , 2002, Journal of clinical pharmacology.

[160]  M. Roth,et al.  Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. , 2001, American journal of respiratory cell and molecular biology.

[161]  C. Heather Ashton,et al.  Pharmacology and effects of cannabis: A brief review , 2001, British Journal of Psychiatry.

[162]  H. Morgenstern,et al.  Marijuana use and increased risk of squamous cell carcinoma of the head and neck. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[163]  C. Ashton Adverse effects of cannabis and cannabinoids. , 1999, British journal of anaesthesia.

[164]  J. Sullivan,et al.  Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons , 1999, The Journal of Neuroscience.

[165]  D. Yurgelun-Todd,et al.  The residual cognitive effects of heavy marijuana use in college students. , 1996, JAMA.

[166]  W. Hall Assessing the health and psychological effects of cannabis use , 1994 .

[167]  M. First,et al.  Marijuana and tobacco smoke gas-phase cytotoxins , 1991, Pharmacology Biochemistry and Behavior.

[168]  J. Buckley,et al.  Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the childrens cancer study group) , 1989, Cancer.

[169]  G. Snyder,et al.  Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. , 1988, Neuroendocrinology.

[170]  G. Duvel The study group. , 1980 .

[171]  W. Paton Pharmacology of marijuana. , 1975, Annual review of pharmacology.